Ashwagandha New Formulation Zenroot™ 84-Day Trial: 1.5% Withanolide Standardization

A randomized double-blind placebo-controlled trial of the new ashwagandha (Withania somnifera) formulation Zenroot™ was published in Advances in Therapy. Standardized to 1.5% total withanolides, 125 mg/day for 84 days meaningfully improved stress, anxiety, mood, and sleep quality in 90 adults. The same period’s March 2026 AshwaSR 60-day trial reported 19.15% cortisol reduction at 300 mg/day.

Zenroot™ trial design

Participants: 90 healthy adults reporting stress.

Intervention: Zenroot™ 125 mg/day (1.5% total withanolides) or placebo. 84 days.

Primary endpoints: Stress score (PSS), anxiety score, mood score, sleep quality score.

Core results

Meaningful stress score reduction: Consistent difference vs placebo across multiple measurement points.

Anxiety score reduction: Meaningful difference.

Mood score improvement: Meaningful difference.

Sleep quality improvement: Improved at multiple measurement points.

Side effects: Mild and not different from placebo.

Withanolides and standardization

Withanolides are the core active molecules of ashwagandha. 30+ types identified, with withanolide A, withaferin A, withanoside IV among the best-studied.

Traditionally clinical trials used KSM-66 extract (5% withanolides), Sensoril (8-10%), and other standardized extracts. This Zenroot uses 1.5% standardization at lower concentration but validates efficacy at 125 mg/day clinical dose.

This implies two things. The clinical value of withanolide concentration standardization (check labels for stated ratios). And various concentration/dose combinations can reach the same effect.

AshwaSR trial comparison

The AshwaSR (ashwagandha root extract sustained release) trial published the same period.

Participants: 60 days, 150 mg or 300 mg/day.

Core results.

60-day cortisol reduction: 19.15% at 300 mg/day, 11.44% at 150 mg/day. Dose-dependent effect.

Stress, anxiety reduction: Meaningful across multiple scales.

Side effects: Generally mild.

The combined message of these two trials is clear. Ashwagandha’s cortisol-reducing effect is consistently validated across formulations and doses.

Mechanism

Ashwagandha’s anti-stress effect through multiple paths.

HPA axis modulation: Partially reduces chronic activation of the hypothalamic-pituitary-adrenal (HPA) axis. Cortisol normalization.

GABA receptor modulation: GABAergic signaling enhancement calms anxiety.

Dopamine, serotonin systems: Some data show neurotransmitter balance effects.

Inflammation reduction: Partially reduces inflammation accompanying chronic stress.

Sleep quality improvement: Indirect effect through stress reduction rather than direct sleep induction.

Withanolide standardization comparison

Standardization differences across commercial ashwagandha extracts.

KSM-66: 5% withanolides. Most extensively researched clinically. General dose 300-600 mg/day.

Sensoril: 8-10% withanolides. Stronger extract. General dose 125-250 mg/day.

Zenroot: 1.5% withanolides. New standardization. Clinical dose 125 mg/day.

AshwaSR: Sustained release formulation. General dose 150-300 mg/day.

Generic powder, extract: Without standardization, withanolide concentration varies widely. Clinical effect prediction is difficult.

Choose products with stated standardization + clinical data.

Who fits

Chronic stress, mild anxiety: First-line adjunct. On top of CBT, exercise, and sleep hygiene foundation.

Sleep quality decline: Matrix option together with this quarter’s magnesium bisglycinate.

Burnout, chronic fatigue: Through HPA axis modulation.

Exercise recovery: Some trials report muscle recovery and exercise performance support.

Testosterone support: Some trials show small testosterone increase in men. Clear clinical recommendation lacking.

Who should be careful

Thyroid disease history: Possible thyroid hormone effects. Consult a clinician for hyperthyroidism, autoimmune thyroid disease.

Autoimmune disease: Possible immune stimulation. Consult a clinician for rheumatoid arthritis, lupus.

Pregnancy/breastfeeding: Some data suggest avoidance during pregnancy. Consult a clinician.

On sedatives or anxiolytics: Possible synergy or interaction. Consult a clinician.

Pre-surgery: Sedative effects may interact with anesthesia. Stop 2 weeks before surgery.

GI sensitive: Empty stomach can irritate. Take with meals.

Daily guide

Dose: Standardized extract 125-600 mg/day clinical range. Check label for standardization ratio.

Timing: For stress targeting, morning. For sleep targeting, evening.

Duration: Assess effect after 4-8 weeks. Continue 3-6 months if effective. Then take a break.

Combinations: Magnesium bisglycinate (sleep), L-theanine (calming), vitamin D, omega-3, exercise, sleep hygiene. Supplement on top of foundations.

Connection to other matrices

Connections to this quarter’s data.

Sleep matrix: Magnesium bisglycinate + glycine + ashwagandha + behavioral intervention (CBT-I).

Stress/burnout matrix: Ashwagandha + exercise + sleep + nutrition + psychological support.

Hormonal matrix: Cortisol and other hormone balance around menopause. Complements critical window hypothesis (MHT).

Aging mechanism matrix: Chronic stress is a path to senescent cell burden and mitochondrial damage. Stress reduction provides multi-layered protection.

Ashwagandha is a powerful tool but not a cure-all. Use within the matrix matched to your stage and target. Solving the root causes of chronic stress (life, work, relationships) cannot be replaced by supplements.